Fig. 1From: Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockadeTargeting FAK in combination with anthracyclines exhibits the most potent cancer cell killing through chemotherapeutic drug screening. A Patient ratios of copy number amplification across different cancer types from TCGA datasets. B-C The correlation analysis between log2 copy numbers and mRNA levels of PTK2 or FAK protein levels in ovarian cancer from TCGA datasets. R.2 and slope non-zero p value were obtained to analyze correlation significance. D-E The overall and progression-free survival analyses between patients with PTK2 high amplification (copy number > 7) and without PTK2 copy number variation for ovarian cancer from TCGA datasets. F-G The cell-killing effects of IN10018 or defactinib in the treatment of different ovarian cancer cell lines (n = 3 per point). H The antitumor effects of IN10018 in the treatment of different ovarian cancer animal models including 6 CDX models and 3 PDX models (n = 3 per group). I The drug details of the chemotherapeutic drug screening. J-K The IC50 comparison between the tested drugs alone (x-axis) or the combination of tested drugs and 3 μM IN10018 (y-axis) in the screening with ovarian cancer cell lines A2780 or SK-OV-3. Data represent mean ± SEM. Log-rank testing was performed for the analysis of statistical significance. The unpaired student's T-test was used for the other statistical analysis. NS means non-significant, *P < 0.05, and **P < 0.01Back to article page